U.S. National Library of Medicine
National Center for Biotechnology Information

Palifermin

Revised: December 21, 2020.

CASRN: 162394-19-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of palifermin during breastfeeding. Because palifermin is a large protein molecule with a molecular weight of 16,300 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. With an average half-life of 4.5 hours, the drug should be eliminated by the mother in 2 days. Because it is administered with potent chemotherapy agents, the persistence of those drugs is probably more relevant. The manufacturer recommends that breastfeeding should be discontinued during treatment with palifermin and for at least 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Palifermin

CAS Registry Number

162394-19-6

Drug Class

Breast Feeding

Lactation

Fibroblast Growth Factors